…and some to hold, avoid or sell

Enquest The Times

The oil and gas developer has undergone “painful debt restructuring” and now faces a lower production outlook from its Kraken field in the North Sea, due to technical problems. Covenants “look under threat”. Sell. 29.75p.

Hikma Pharmaceuticals Investors Chronicle

The pharma group has cut the revenue guidance for its generics division, citing increased competition. Profits from injectables have fallen 1% and branded products face adverse currency movements. Sell. £12.12.

The Times

Shares in the energy services provider “could claw back some value if the recovery in US shale continues”. Its Titan division, which sells equipment to complete wells, could compensate for any dip in new drilling. Hold. 420p.

Oxford Biomedica Investors Chronicle

Revenues have risen on encouraging trial data, but much still depends on the future success of OXB’S leukaemia treatment CTL019 approval. Take profits, as downside risk is difficult to quantify. Sell. 8.9p.

The Times

The Provvy’s share price has recovered from its recent low, but its value has nearly halved since mid-august as it struggles to implement new technology. It remains over-exposed to the overborrowed. Sell. 600p.

Wood Group Investors Chronicle

The oil services group is faced with a “moribund outlook” as trading remains tough. Cost synergies from the takeover of Amec Foster Wheeler have been oversold, and the SFO’S investigation of Unaoil now includes Wood. Sell. 568p.